VistaGen Therapeutics(US:VTGN) Globenewswire·2026-01-22 15:45Core Viewpoint - Bernstein Liebhard LLP is reminding investors of Vistagen Therapeutics, Inc. about a deadline related to a securities fraud class action lawsuit against the company [1]. Group 1: Lawsuit Details - A class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors who purchased Vistagen common stock between April 1, 2024, and December 16, 2025, alleging violations of the Securities Exchange Act of 1934 [3]. - The lawsuit claims that the defendants made misrepresentations regarding the Company's Phase 3 PALISADE-3 trial study of fasedienol, which is being developed for the acute treatment of social anxiety disorder [4]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiff for the class must file papers by March 16, 2026, with the role involving directing the litigation on behalf of other class members [5]. - Participation as a lead plaintiff is not required to share in any potential recovery, and all representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for its clients since 1993 and has represented both individual investors and large public and private pension funds [6]. - The firm has been recognized for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].